Frequencies of red blood cell major blood group antigens and phenotypes in the Chinese Han population from Mainland China

2016 ◽  
Vol 43 (4) ◽  
pp. 226-235 ◽  
Author(s):  
Y. Yu ◽  
C. Ma ◽  
X. Sun ◽  
X. Guan ◽  
X. Zhang ◽  
...  
2019 ◽  
Vol 34 (6) ◽  
pp. 496-503
Author(s):  
Arwa Z. Al-Riyami ◽  
Ali Al-Marhoobi ◽  
Saif Al-Hosni ◽  
Sabah Al Mahrooqi ◽  
Michael Schmidt ◽  
...  

2019 ◽  
Author(s):  
Shan Zou ◽  
Lishan Wu ◽  
Zeliang Chen ◽  
Hongxiao Li ◽  
Hongjuan Chen ◽  
...  

Abstract Background: Numerous studies have demonstrated that patients with non-O blood groups have higher risk for venous thromboembolism than those with O blood group. However, it has remained unknown about the effect of ABO blood groups on warfarin dose requirements in patients receiving anticoagulation in Chinese Han population. The study aimed to investigate the influence of ABO blood groups on warfarin dose requirements in Chinese Han population. Methods: A retrospective study was conducted in the First Affiliated Hospital of Shantou University Medical College in Southern China. Three hundreds and 58 patients with confirmed diagnosis of deep venous thromboembolism and atrial fibrillation were included. Frequency of blood groups and warfarin dose requirements were determined. Results: Of 358 patients with deep venous thromboembolism and atrial fibrillation, 111 patients had blood group A (31.01%), 104 patinets had blood group B (29.05%), 20 patients had blood group AB (5.59%), and 123 patients had blood group O (34.36%). The patients with O blood group had a lower warfarin dose requirements compared with those with A, B and AB blood group. Conclusion: Our study showed that patients with non-O blood groups require higher doses of warfarin.


Hematology ◽  
2016 ◽  
Vol 2016 (1) ◽  
pp. 452-456 ◽  
Author(s):  
James C. Zimring ◽  
Krystalyn E. Hudson

Abstract In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell (RBC) alloantigens in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology, and B-cell biology. Moreover, these cellular processes differ to some extent with regard to transfused RBCs as compared with other better-studied immune barriers (eg, infectious disease, vaccines, and solid organ transplantation). The current work focuses on illustrating the current paradigm of humoral immunity, with a specific focus on particulars of RBC alloimmunization and recent advances in the understanding thereof.


Vox Sanguinis ◽  
2010 ◽  
Vol 98 (4) ◽  
pp. 554-559 ◽  
Author(s):  
F. Zhu ◽  
S. Tao ◽  
X. Xu ◽  
Y. Ying ◽  
X. Hong ◽  
...  

Pancreas ◽  
2019 ◽  
Vol 48 (9) ◽  
pp. e65-e66 ◽  
Author(s):  
Mengqi Liu ◽  
Shunrong Ji ◽  
Wenyan Xu ◽  
Wensheng Liu ◽  
Yi Qin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document